Presentations – Belem HIV Clinical Forum 2019

 

Tuesday 10 September 2019

 Session 1 - Clinical Consideration when choosing ART regimens
Chairs: Charles Boucher & Tânia Vergara
 

Simplification of drug regimens
Pedro Cahn, MD, PhD - Fundación Huésped, Buenos Aires, Argentina

 

Charles Boucher, MD, PhDResistance considerations when choosing INSTIs
Charles Boucher, MD, PhD - Erasmus Medical Center, Rotterdam, The Netherlands

 

 Pharmacology considerations when choosing INSTIs
Charles Flexner, MD - Johns Hopkins University School of Medicine, Baltimore, USA
 Clinical Case
Gustavo Albino Pinto Magalhães, MD, PhD - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
 Session 2 - Optimal Use of INSTIs in the Clinic
Chairs: Maria do Perpetuo Socorro Costa Correa & Mauro Schechter
 Experience with Dolutegravir in first line in Brazil
Ricardo Diaz, MD - Universidade Federal de São Paulo, São Paulo, Brazil
 

Mark Nelson, MDSwitching to INSTIs based treatment in viral suppressed patients
Mark Nelson, MD, FRCP - Chelsea and Westminster Hospital, London, United Kingdom

 INSTIs use in women at child-bearing age - NTD risks
Sharon Walmsley, CM, MD, FRCPC - University Health Network, Toronto, Canada
 Session 3 - INSTIs in challenging patients
Chairs: Ricardo Diaz & José Valdez Madruga
 Role of INSTIs in prevention
Mauro Schechter, MD, PhD - Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
 

Clinical management of HIV-TB co-infected patients
Mark Nelson, MD, FRCP - Chelsea and Westminster Hospital, London, United Kingdom

 Clinical Case
Maria do Perpetuo Socorro Costa Correa, MD, - Sociedade Brasileira de Infectologia, Bélem, Brazil
 Session 4 - Future of HIV Therapy
Chairs: Charles Boucher & Sharon Walmsley
 PrEP in young: does the incidence of STI increase?
José Valdez Madruga, MD - CRT/AIDS, São Paulo, Brazil
 ​Long Acting Antivirals & Novel delivery systems
(Not yet available)

Charles Flexner, MD - Johns Hopkins University School of Medicine, Baltimore, USA